A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06138132 |
Recruitment Status :
Recruiting
First Posted : November 18, 2023
Last Update Posted : April 30, 2024
|
Sponsor:
Stanford University
Collaborator:
Kyverna Therapeutics
Information provided by (Responsible Party):
Jeffrey Dunn MD, Stanford University
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Recruiting |
---|---|
Estimated Primary Completion Date : | June 2027 |
Estimated Study Completion Date : | June 2027 |
Publications: